One study, in which biopsies were taken from patients before and after starting vemurafenib therapy, showed that BRAF inhibition was associated with increased melanoma antigen expression, increased CD8+ T-cell infiltrate and decreased immunosuppressive cytokines in tumours of patients with metastatic melanoma. The gene discussed is BRAF; the disease is neoplasm.